TY - JOUR
T1 - Treatment and overall survival of four types of non-metastatic periampullary cancer
T2 - nationwide population-based cohort study
AU - de Jong, Evelien J. M.
AU - van der Geest, Lydia G.
AU - Besselink, Marc G.
AU - Bouwense, Stefan A. W.
AU - Buijsen, Jeroen
AU - Dejong, C. H. C.
AU - Koerkamp, Bas G.
AU - Heij, Lara R.
AU - de Hingh, Ignace H. J. T.
AU - Hoge, Chantal
AU - Kazemier, Geert
AU - van Laarhoven, Hanneke W. M.
AU - de Meijer, Vincent E.
AU - Dutch Pancreatic Cancer Group
AU - Stommel, Martijn W. J.
AU - Tjan-Heijnen, Vivianne C. G.
AU - Valkenburg-van Iersel, Liselot B. J.
AU - Wilmink, Johanna W.
AU - Geurts, Sandra M. E.
AU - de Vos-Geelen, Judith
N1 - Funding Information: VM reports a VENI grant by the Netherlands Organization for Scientific Research (NWO; grant #09150161810030) and a grant from the Dutch Ministry of Economic Affairs (Health ∼ Holland Public Private Partnership grant #PPP-2019-024). All outside the submitted work; IDH received grants from Roche and RanD Biotechnology. All outside the submitted work; Funding Information: The authors thank the registration team of the Netherlands Comprehensive Cancer Organisation (IKNL) for the collection of data for the Netherlands Cancer Registry as well as IKNL staff for scientific advice. Publisher Copyright: © 2022 The Author(s)
PY - 2022/9
Y1 - 2022/9
N2 - Background: Periampullary adenocarcinoma consists of pancreatic adenocarcinoma (PDAC), distal cholangiocarcinoma (DC), ampullary cancer (AC), and duodenal adenocarcinoma (DA). The aim of this study was to assess treatment modalities and overall survival by tumor origin. Methods: Patients diagnosed with non-metastatic periampullary cancer in 2012–2018 were identified from the Netherlands Cancer Registry. OS was studied with Kaplan–Meier analysis and multivariable Cox regression analyses, stratified by origin. Results: Among the 8758 patients included, 68% had PDAC, 13% DC, 12% AC, and 7% DA. Resection was performed in 35% of PDAC, 56% of DC, 70% of AC, and 59% of DA. Neoadjuvant and/or adjuvant therapy was administered in 22% of PDAC, 7% of DC, 7% of AC, and 12% of DA. Three-year OS was highest for AC (37%) and DA (34%), followed by DC (21%) and PDAC (11%). Adjuvant therapy was associated with improved OS among PDAC (HR = 0.62; 95% CI 0.55–0.69) and DC (HR = 0.69; 95% CI 0.48–0.98), but not AC (HR = 0.87; 95% CI 0.62–1.22) and DA (HR = 0.85; 95% CI 0.48–1.50). Conclusion: This retrospective study identified considerable differences in treatment modalities and OS between the four periampullary cancer origins in daily clinical practice. An improved OS after adjuvant chemotherapy could not be demonstrated in patients with AC and DA.
AB - Background: Periampullary adenocarcinoma consists of pancreatic adenocarcinoma (PDAC), distal cholangiocarcinoma (DC), ampullary cancer (AC), and duodenal adenocarcinoma (DA). The aim of this study was to assess treatment modalities and overall survival by tumor origin. Methods: Patients diagnosed with non-metastatic periampullary cancer in 2012–2018 were identified from the Netherlands Cancer Registry. OS was studied with Kaplan–Meier analysis and multivariable Cox regression analyses, stratified by origin. Results: Among the 8758 patients included, 68% had PDAC, 13% DC, 12% AC, and 7% DA. Resection was performed in 35% of PDAC, 56% of DC, 70% of AC, and 59% of DA. Neoadjuvant and/or adjuvant therapy was administered in 22% of PDAC, 7% of DC, 7% of AC, and 12% of DA. Three-year OS was highest for AC (37%) and DA (34%), followed by DC (21%) and PDAC (11%). Adjuvant therapy was associated with improved OS among PDAC (HR = 0.62; 95% CI 0.55–0.69) and DC (HR = 0.69; 95% CI 0.48–0.98), but not AC (HR = 0.87; 95% CI 0.62–1.22) and DA (HR = 0.85; 95% CI 0.48–1.50). Conclusion: This retrospective study identified considerable differences in treatment modalities and OS between the four periampullary cancer origins in daily clinical practice. An improved OS after adjuvant chemotherapy could not be demonstrated in patients with AC and DA.
UR - http://www.scopus.com/inward/record.url?scp=85124137503&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.hpb.2022.01.009
DO - https://doi.org/10.1016/j.hpb.2022.01.009
M3 - Article
C2 - 35135724
SN - 1365-182X
VL - 24
SP - 1433
EP - 1442
JO - HPB
JF - HPB
IS - 9
ER -